Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
A Leonetti, S Sharma, R Minari, P Perego… - British journal of …, 2019 - nature.com
Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …
Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
M Tsuboi, RS Herbst, T John, T Kato… - … England Journal of …, 2023 - Mass Medical Soc
Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …
[HTML][HTML] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
D Planchard, PA Jänne, Y Cheng… - … England Journal of …, 2023 - Mass Medical Soc
Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
[HTML][HTML] Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer …
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer …
[HTML][HTML] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
SS Ramalingam, J Vansteenkiste… - … England Journal of …, 2020 - Mass Medical Soc
Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer: updated results from the phase III randomized ADAURA trial
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F **e, F Wang, L Fu - Journal of Hematology & Oncology, 2022 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced …
T Reungwetwattana, K Nakagawa, BC Cho… - Journal of Clinical …, 2018 - ascopubs.org
Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated …
receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated …
Radiation therapy for brain metastases: an ASTRO clinical practice guideline
Purpose This guideline provides updated evidence-based recommendations addressing
recent developments in the management of patients with brain metastases, including …
recent developments in the management of patients with brain metastases, including …